GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Goodwill-to-Asset

Proteomics International Laboratories (ASX:PIQ) Goodwill-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Proteomics International Laboratories's Goodwill for the quarter that ended in Dec. 2024 was A$0.00 Mil. Proteomics International Laboratories's Total Assets for the quarter that ended in Dec. 2024 was A$7.02 Mil. Therefore, Proteomics International Laboratories's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 was 0.00.


Proteomics International Laboratories Goodwill-to-Asset Historical Data

The historical data trend for Proteomics International Laboratories's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories Goodwill-to-Asset Chart

Proteomics International Laboratories Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Proteomics International Laboratories Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Proteomics International Laboratories's Goodwill-to-Asset

For the Biotechnology subindustry, Proteomics International Laboratories's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteomics International Laboratories's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's Goodwill-to-Asset falls into.


;
;

Proteomics International Laboratories Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Proteomics International Laboratories's Goodwill to Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Goodwill to Asset (A: Jun. 2024 )=Goodwill/Total Assets
=0/10.875
=0.00

Proteomics International Laboratories's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill to Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/7.021
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteomics International Laboratories  (ASX:PIQ) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Proteomics International Laboratories Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteomics International Laboratories Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories Headlines

No Headlines